Eighteenth International Kidney Cancer Symposium

November 15-16, 2019
Miami, Florida

Conference Program and Agenda

For more information about the Kidney Cancer Association and about the Eighteenth International Kidney Cancer Symposium in Miami go to:

Kidney Cancer Association
KidneyCancer.org
Wireless Internet Instructions

- Connect to wireless network **TND Events**
- Enter access code **KCA2019** and agree to terms and conditions
- Need assistance? Call 305.591.6444

Audience Response System

To participate in audience polls and submit questions to the panel, please follow these steps:

1. Connect to Wi-Fi network
2. Open browser on your device and enter **vpoll.mobi** in the address bar
3. Enter the access code: **IKCS** and click the Join button
4. At the Login Screen select the polling session: **IKCS19**
Welcome to Miami and the 18th International Kidney Cancer Symposium!

We are delighted to have you with us and hope that you will find the Symposium productive and educational. This special event would not have been possible without the many hours of hard work by the Scientific Program Committee – Brian M. Shuch, M.D., Lauren C. Harshman, M.D. – Co-Chairs, Matthew T. Campbell, M.D., M.S. Chung-Han Lee, M.D., Ph.D. Eric A. Singer, M.D., MA, MS, FACS, Laura Wood, R.N., MSN, OCN, Rodolfo Reis, M.D., Ph.D.. They have put together a comprehensive program that is informative and will provide a basis for your continued work in kidney cancer.

Since 1990, the Kidney Cancer Association has dedicated itself to the eradication of kidney cancer and to improving care, stimulating research, and increasing survival of kidney cancer patients worldwide. We are the only organization of its kind to serve kidney cancer patients, their families, and physicians around the world. As we work to globalize our organization, we hope to continue our collaboration with you so that we may be of further assistance to you and your patients.

Please note that as part of our commitment to environmental responsibility, this year’s presentations and abstracts will be online. Information on how to access these materials can be found in your book. Your comments are welcome.

Thank you again for joining us for the 18th International Kidney Cancer Symposium. If there is anything we can do to help you during the next two days, please do not hesitate to call on us.

Christopher G. Wood, Sr., M.D., FACS
Chair, Board of Directors
Kidney Cancer Association

Gretchen E. Vaughan
President and CEO
Kidney Cancer Association
The Kidney Cancer Association Would Like To Thank Our 2019 Board Members!

Board of Directors 2019
Lisa Alderson
Ronald M. Bukowski, M.D.
Noah Buntman
Tessa Churchill, M.D.
Craig DePriester
Jamie Graves
Bradley C. Leibovich, M.D, FACS
Eric Perakslis, Ph.D.
David Perry
William Perry
Denise Richards
Shelley Robson
Nicholas J. Vogelzang, M.D.
Christopher G. Wood, Sr., M.D., FACS
Ruben Ybarra

Medical Steering Committee 2019
Laurence Albige, M.D. Ph.D
Axel Bex, M.D., Ph.D.
Ronald M. Bukowski, M.D.
James Hsieh, M.D.
Thomas E. Hutson, D. O., Pharm.D., FACP
Jose A Karam, M.D., FACS
Chung-Han (Joe) Lee, M.D., Ph.D.
Bradley C. Leibovich, M.D., FACS
W. Kimryn Rathmell, M.D., Ph.D.
Brian I. Rini, M.D.
Walter M. Stadler, M.D., FACP
Nizar M. Tannir, M.D., FACP
Christopher G. Wood, Sr., M.D., FACS

Nursing Advisory Board 2019
Nancy Ainslie, R.N.
Laurie Appleby, R.N., NP
Julia Batten, R.N.
Trish Creel, R.N., OCN, CCRP
Patricia Fischer, R.N., MSN, OCN
Jan Jackson, R.N., ADN
Nancy Moldawer, R.N., MSN
Virginia Seery, R.N.
Laura Wood, R.N., MSN, OCN
The Kidney Cancer Association presents the

Eighteenth International Kidney Cancer Symposium

November 15-16, 2019

Overview:
Bringing together key individuals and representatives from leading laboratories and centers working with renal cell carcinoma, the Eighteenth International Kidney Cancer Symposium seeks to provide a forum for the exchange of ideas and information that will continue to frame directions for future research and treatment.

Target Audience:
This meeting is directed to medical oncologists, urologists, and scientists involved in the clinical and research aspects of renal cell carcinoma.
The Kidney Cancer Association presents the

Eighteenth International Kidney Cancer Symposium

Moshe C. Ornstein, M.D., MA
Cleveland Clinic
Cleveland, OH

Sumanta Kumar Pal, M.D.
City of Hope
Comprehensive Cancer Center
Duarte, CA

Allan J. Pantuck, M.D.
UCLA Medical Center
Los Angeles, CA

Ivan Pedrosa, M.D.
University of Texas
Southwestern Medical Center
Dallas, TX

Phillip Pignataro, M.D.
Johns Hopkins Medical Center
Baltimore, MD

Mark Preston, M.D., MPH
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Boston, MA

W. Kimryn Rathmell, M.D., Ph.D.
Vanderbilt University
Medical Center
Nashville, TN

Meredith M. Regan, Sc.D.
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Kerry L. Reynolds, M.D.
Massachusetts General Hospital
Boston, MA

Steve Rowe, M.D.
Johns Hopkins Medical Center
Baltimore, MD

Bianca D. Santomosso, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center
New York, NY

Sasan Setoodeh, M.D.
University of Texas
Southwestern Medical Center
Dallas, TX

Elad Sharon, M.D., MPH
National Institute of Health
Washington, DC

Arlene Sharpe, M.D., Ph.D.
Harvard Medical School
Boston, MA

Bianca Signoretti, M.D.
Dana Farber Cancer Institute
Boston, MA

Andrey Soares, M.D.
LACOG
Paulista Oncology Center
Hospital Israelita Albert Einstein
São Paulo, Brazil

Sandy Srinivas, M.D.
Stanford University
Palo Alto, CA

Walter M. Stadler, M.D., FACP
Comprehensive Cancer Center
University of Chicago Medicine
Chicago, IL

Robert G. Uzzo, M.D., MBA, FACS
Fox Chase Cancer Center
Philadelphia, PA

Ulka Vaishampayan, M.D.
Karmanos Cancer Center
Detroit, MI

Nicholas J. Vogelzang, M.D.
Comprehensive Cancer Centers of America
Las Vegas, NV

Martin H. Voss, M.D.
Memorial Sloan Kettering
New York, NY

Yinghong Wang, M.D., Ph.D., MSc
University of Texas
M.D. Anderson Cancer Center
Houston, TX

Zhen J. Wang, M.D.
University of California - San Francisco
San Francisco, CA

Christopher G. Wood, Sr., M.D., FACS
University of Texas
M.D. Anderson Cancer Center
Houston, TX

Haris Zahoor, M.D., MS
University of Southern California
Los Angeles, CA

Stênio de Cassio Zequi, M.D.
A.C. Camargo Cancer Center
São Paulo, Brazil

Tian Zhang, M.D., MHS
Duke University Medical Center
Durham, NC

Speakers (Continued)
Friday, November 15, 2019

8:00-8:10 am  Welcome and Demographic Questions
Christopher G. Wood, Sr., M.D., FACS
Gretchen E. Vaughan
Lauren C. Harshman, M.D.

Current Understanding and Management of Rare Kidney Cancer Subtypes
Moderators: Sabina Signoretti, M.D., Moshe Ornstein, M.D., MA

8:10-8:22 am  Updates in the WHO Kidney Cancer Classification Schemes
Michelle S. Hirsch, M.D., Ph.D.

8:22-8:32 am  Importance of Tumor Profiling for Rare Histology Variants
Ying-Bei Chen, M.D., Ph.D.

8:32-8:42 am  New Insights in Biology of Renal Medullary Cancer
Nizar M. Tannir, M.D., FACP

8:42-8:52 am  Insights into the Biology of Translocation-Associated (TFE3) Kidney Cancer
Eric C. Kauffman, M.D.

DEBATE: Optimal First Line Therapy for Rare Kidney Cancer Variants (Non-Clear Cell)

8:52-8:59 am  PRO-IO
Primo N. Lara, Jr. M.D.

8:59-9:06 am  PRO-Biologic Therapy
Matthew T. Campbell, M.D., MS

9:06-9:16 am  Abstract: Surgical Insights for Variant Histology
Gennady Bratslavsky, M.D.

9:16-9:23 am  Abstract: Identification of Oncocytic Neoplasms with Cyclin D1 Immunohistochemistry
Neil Mendhiratta, M.D., MS

9:23-9:30 am  Abstract: Effects of Immune Checkpoint Inhibitors on the Morphology of Renal Cell Carcinoma
Sasan Setoodeh, M.D.

9:30-9:40 am  Questions and Answers

9:40-9:55 am  Break

Management of the Localized Small Renal Mass
Moderators: Eric A. Singer, M.D., MA, MS, FACS
Mark Preston, M.D., MPH

DEBATE: Meaningful Endpoints for Surgical Trials for Localized RCC

9:57-10:04 am  PRO-Local/Regional Recurrence
Steven C. Campbell, M.D., Ph.D.

10:04-10:11 am  PRO-Distant Recurrence
Sumanta Kumar Pal, M.D.

10:11-10:18 am  PRO-Renal Function
William C. Huang, M.D.

DEBATE: Management of the Complex Cystic Mass (Bosniak 3/4)

10:20-10:27 am  PRO-Surveillance
Alexander Kutikov, M.D.

10:27-10:34 am  PRO-Surgical Treatment
Stênio de Cássio Zequi, M.D.

10:34-10:44 am  What is the Current Role for Radiation in Early Stage RCC?
Rodney J. Ellis, M.D.

DEBATE: What is the Optimal Management of Post-Ablation Recurrences

10:46-10:53 am  PRO-Partial Nephrectomy
Jose A. Karam, M.D., FACS

10:53-11:00 am  PRO-Repeat Ablation
Raj Ayyagari, M.D.

11:00-11:07 am  PRO-Surveillance
Gopal Gupta, M.D., FACS

11:07-11:12 am  Questions

Immune-Mediated Toxicity: What, Why & How to Manage
Moderators: Mehmet A. Bilen, M.D.
Sarah Abou Alaiwi, M.D.

11:12-11:27 am  OVERVIEW: IRAEs and Establishing an Immune-Related Adverse Event (IRAE) Management Team
Kerry L. Reynolds, M.D.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:27-11:37 am</td>
<td>Current Management Strategies for Immune Related Pneumonitis</td>
<td>Raja E. Abdulnour, M.D.</td>
</tr>
<tr>
<td>11:37-11:47 am</td>
<td>Current Management Strategies for Immune Related Colitis</td>
<td>Yinghong Wang, M.D., Ph.D., MSc</td>
</tr>
<tr>
<td>11:47-11:57 am</td>
<td>Current Management Strategies for Immune Related Neurologic Toxicity</td>
<td>Bianca D. Santomosso, M.D., Ph.D.</td>
</tr>
<tr>
<td>11:57-12:07 pm</td>
<td>Current Management Strategies for Immune Related Cardiac Toxicity</td>
<td>Javid Moslehi, M.D.</td>
</tr>
<tr>
<td>12:07-12:12 pm</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>12:12-1:22 pm</td>
<td><strong>A Combination Therapy for the First-Line Treatment of Advanced RCC</strong></td>
<td></td>
</tr>
<tr>
<td>1:22-1:27 pm</td>
<td>Introduction to the Eugene P. Schonfeld Memorial Lecture</td>
<td>Toni K. Choueiri, M.D.</td>
</tr>
<tr>
<td>1:27-2:07 pm</td>
<td><strong>Eugene P. Schonfeld Memorial Lecture</strong></td>
<td>W. Kimryn Rathmell, M.D., Ph.D.</td>
</tr>
<tr>
<td>2:07-2:12 pm</td>
<td>Introduction</td>
<td>Lisa Derosa, M.D., Ph.D.</td>
</tr>
<tr>
<td>2:12-2:32 pm</td>
<td>Changing Paradigms in Statistical Interpretation—Do We Still Need the p Value?</td>
<td>Pavlos Msaouel, M.D., Ph.D.</td>
</tr>
<tr>
<td>2:32-2:37 pm</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>2:37-2:42 pm</td>
<td>Introduction</td>
<td>Michael A.S. Jewett, M.D., FRCSC</td>
</tr>
<tr>
<td>2:42-3:02 pm</td>
<td>How Artificial Intelligence Can Improve Cancer Care</td>
<td>Mark Michalski, M.D.</td>
</tr>
<tr>
<td>3:02-3:07 pm</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>3:07-3:17 pm</td>
<td>Overview of the UTSW SPORE</td>
<td>James Brugarolas, M.D., Ph.D.</td>
</tr>
<tr>
<td>3:17-3:27 pm</td>
<td>Spotlight on Research From UTSW SPORE</td>
<td>Srinivas Malladi, Ph.D.</td>
</tr>
<tr>
<td>3:27-3:37 pm</td>
<td>Overview of the Harvard SPORE</td>
<td>Toni K. Choueiri, M.D.</td>
</tr>
<tr>
<td>3:37-3:47 pm</td>
<td>Spotlight on Research from Harvard SPORE</td>
<td>David A. Braun, M.D., Ph.D.</td>
</tr>
<tr>
<td>3:47-3:57 pm</td>
<td>Advocating for Funding: An Advocates Perspective to Increasing Resources</td>
<td>Bryan Lewis</td>
</tr>
<tr>
<td>3:57-4:07 pm</td>
<td>Unmet Needs in the Patient Experience: A Global Survey</td>
<td>Deborah Maskens, MA, MSD</td>
</tr>
<tr>
<td>4:07-4:11 pm</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>4:11-4:26 pm</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>4:28-4:38 pm</td>
<td>PRO-Active Surveillance</td>
<td>Michael R. Harrison, M.D.</td>
</tr>
<tr>
<td>4:38-4:48 pm</td>
<td>PRO-Monotherapy</td>
<td>Walter M. Stadler, M.D., FACP</td>
</tr>
<tr>
<td>4:48-4:58 pm</td>
<td>PRO-Combination Therapy</td>
<td>André P. Fay, M.D., Ph.D.</td>
</tr>
<tr>
<td>4:58-5:08 pm</td>
<td>Aiming to Personalize Immunotherapy with Existing and Emerging Biomarkers</td>
<td>Tian Zhang, M.D., MHS</td>
</tr>
<tr>
<td>5:08-5:18 pm</td>
<td>Managing RCC in Challenging Immune Milieu</td>
<td>Elad Sharon, M.D., MPH</td>
</tr>
</tbody>
</table>
5:18-5:28 pm  Optimal Role of Consolidative Surgery in the IO Era
   Viraj Master, M.D., Ph.D., FACS

5:28-5:35 pm  Abstract: Incidence of Occult Brain Metastases Detected at Study Screening in Patients with Advanced Renal Cell Carcinoma
   Ritesh Kotecha, M.D.

5:35-5:42 pm  Abstract: Results from a Randomised Phase 1/2 Trial Evaluating the Safety and Anti-Tumor Activity of Anti-PD-1 (MEDI0680)/Anti-PD-L1 (Durvalumab) vs Anti-PD-1 (Nivolumab) Alone in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
   Martin H. Voss, M.D.

5:42-5:52 pm  Questions

6:00-8:00 pm  Reception and Posters in the Crystal Ballroom Terrace

Saturday, November 16, 2019

8:00-8:05 am  Welcome
   Brian M. Shuch, M.D.

8:05-8:15 am  CAIX Imaging
   Allan J. Pantuck, M.D.

8:15-8:25 am  Sestabimi Imaging
   Steve Rowe, M.D.

8:25-8:35 am  MRI- Clear Cell Score
   Ivan Pedrosa, M.D.

8:35-8:45 am  Metabolic Imaging
   Zhen J. Wang, M.D.

8:45-8:52 am  Abstract: Radiomic Signatures of CD8+ T Cell Infiltration and PD-L1 Expression in Clear-Cell Renal Cell Carcinoma (ccRCC)
   Haris Zahoor, M.D., MS

8:52-8:59 am  Abstract: An Exploratory Study of 89Zr-DFO Atezolizumab ImmunoPET/CT in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
   Isaac A. Bowman, M.D.

8:59-9:09 am  Questions

Top Abstract Session
Moderators:  Bradley C. Leibovich, M.D., FACS
            Sandy Srinivas, M.D.

9:09-9:16 am  Circulating Tumor DNA (ctDNA) Results in 110 Patients with Advanced Renal Cell Carcinoma
   Ritesh Kotecha, M.D.

   Chirag Krishna, M.D.
9:23-9:30 am  Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1 Immune Checkpoint Inhibitor in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC): Results of an Interim Analysis
Chung-Han Lee, M.D., Ph.D.

9:30-9:37 am  Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Meredith M. Regan, Sc.D.

Cristiane Bergerot, Ph.D.

9:42-9:49 am  Overall Survival from the Phase 3 TIVO-3 Study in Advanced Renal Cell Carcinoma
Sumanta Kumar Pal, M.D.

9:49-9:59 am  Questions

Keynote II

9:59-10:23 am  Discovery of New IO Targets Leveraging CRISPR
Arlene Sharpe, M.D., Ph.D.

10:23-10:33 am  Questions

10:33-11:45 am  CME Symposium
How I Think, How I Treat: Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC
Chair and Presenter: Toni K. Choueiri, M.D.
Presenters: Hans J. Hammers, M.D., Ph.D.
Rana McKay, M.D.

Emerging Kidney Cancer Targets
Moderators: Charles G. Drake, M.D., Ph.D.
Ari Hakimi, M.D.

11:45-11:57 am  T-Cell Differentiation and TCF
Haydn T. Kissick, Ph.D.

11:57-12:09 pm  ERV
Aguirre deCubas, Ph.D.

12:09-12:21 pm  MDSCs & Innate Cytokines
Charles G. Drake, M.D., Ph.D.

12:21-12:33 pm  QSOX
Thai H. Ho, M.D., Ph.D.

12:33-12:45 pm  Radiation to Prime the Immune System
Hans J. Hammers, M.D., Ph.D.

12:45-12:57 pm  EZH2
Leigh Ellis, Ph.D.

12:57-1:09 pm  Abstract: Prognostic Significance and Immune Correlates of CD73 Expression in Renal Cell Carcinoma (RCC)
Abhishek Tripathi, M.D.

1:09-1:12 pm  Abstract: Loss of SETD2 is Associated with Dysregulation of Protein Translation in Clear Cell Renal Cell Carcinoma
Scott M. Haake, M.D.

1:21-1:26 pm  Questions

"Wood Fire" Tumor Board
Moderator: Christopher G. Wood, Sr., M.D., FACS

1:26-2:26 pm  Panelists
M. Dror Michaelson, M.D., Ph.D.
Ulka Vaishampayan, M.D.
Robert A. Figlin, M.D., FACP
Robert G. Uzzo, M.D., MBA, FACS
Vitaly Margulis, M.D.
Stephen A. Boorjian, M.D.

2:26-2:31 pm  Closing Comments
Brian M. Shuch, M.D.
Thank you to our sponsors

SILVER SPONSORS

EMD Serono

Pfizer

BRONZE SPONSORS

Bristol-Myers Squibb

EXELIXIS

EXHIBITORS

Eisai

MERCK

NOVARTIS

SPONSOR

AVEO Oncology

Kidney Cancer Association

KidneyCancer.org
Please note:

All presentations and videos will be available to download as PDF files or view on the following websites approximately 2 weeks following the symposium.

To download presentations, go to:
www.euikcs.com/kca/miami2019

To view videos, go to:
You’re Invited

Please join us for a cocktail reception on the Crystal Ballroom Patio. Friday, November 15, 2019 Immediately following the program until 8:00 PM

Sponsored by:

EMD SERONO

Pfizer
About the Kidney Cancer Association

The Kidney Cancer Association is a charitable organization made up of patients, family members, survivors, physicians, researchers and other healthcare professionals globally. The Association was founded in 1990 by a small group of patients, including Eugene P Schonfeld, Ph.D., and medical doctors in Chicago, Illinois, and has grown to become the leading support organization for people diagnosed with kidney cancer.

To accomplish our goal of a world without kidney cancer, we offer a variety of services:

- We provide education to patients and families and help those with kidney cancer cope with the disease.
- We advance medical research and provide education of physicians and nurses.
- We serve as an advocate on behalf of patients at the state and federal levels.

One of the Association’s most important contributions is its support of the physicians and nurses who care for kidney cancer patients. Through our educational activities we help ensure that the latest medical advances and best practices are shared. Our global medical conferences bring together the world’s leading technology and treatment options.

–Gretchen E. Vaughan, President and CEO, Kidney Cancer Association

Mail Donations To:

Kidney Cancer Association
9450 SW Gemini Drive #38269
Beaverton, OR 97008-7105
Tel: 847-332-1051
office@kidneycancer.org

KidneyCancer.org
Fifteenth European International Kidney Cancer Symposium

24-25 April 2020
Hilton Antwerp Old Town
Antwerp, Belgium

Save the Date

For more information about the Kidney Cancer Association and about the Fifteenth European International Kidney Cancer Symposium in Antwerp go to:

Kidney Cancer Association
KidneyCancer.org
Nineteenth International Kidney Cancer Symposium

November 6-7, 2020
Trump National Doral Hotel
Miami, Florida

Save the Date

For more information about the Kidney Cancer Association and about the Nineteenth International Kidney Cancer Symposium in Miami go to: KidneyCancer.org
For more information about the Kidney Cancer Association and about the Twentieth International Kidney Cancer Symposium in Austin go to:

Kidney Cancer Association
KidneyCancer.org
2020 GRANT TIMELINE

SAVE THE DATES

ADVANCED DISCOVERY AWARDS
AND
YOUNG INVESTIGATOR AWARDS

- March 18, 2020: Call for Letters of Intent
- May 20, 2020: Final Day to submit Letters of Intent
- June 10, 2020: Final Day that Meritorious Proposals will be notified to proceed with preparation and submission of a full proposal for evaluation
- August 5, 2020: Final Day to submit Full Proposal for academic review
- September 16, 2020: The Award winners will be notified and announced publicly
- October 7, 2020: Awards will be distributed to award winners

Kidney Cancer Association
KidneyCancer.org
EXPLORE THE DATA at BAVENCIO.COM
Discover the impact of real-world evidence in first-line advanced RCC

Visit the Novartis booth to learn more about the PRINCIPAL real-world study

RCC, renal cell carcinoma.